Compass Therapeutics (CMPX) Projected to Post Earnings on Thursday

Compass Therapeutics (NASDAQ:CMPX) is expected to issue its quarterly earnings data before the market opens on Thursday, March 20th. Analysts expect the company to announce earnings of ($0.10) per share for the quarter.

Compass Therapeutics (NASDAQ:CMPX) last announced its earnings results on Thursday, February 27th. The company reported ($0.11) EPS for the quarter, missing the consensus estimate of ($0.10) by ($0.01). On average, analysts expect Compass Therapeutics to post $0 EPS for the current fiscal year and $0 EPS for the next fiscal year.

Compass Therapeutics Price Performance

Shares of CMPX opened at $2.31 on Wednesday. The company has a market capitalization of $319.43 million, a P/E ratio of -6.24 and a beta of 1.19. Compass Therapeutics has a one year low of $0.77 and a one year high of $4.08. The business’s 50 day simple moving average is $2.84 and its 200-day simple moving average is $2.06.

Analyst Upgrades and Downgrades

CMPX has been the topic of several recent analyst reports. Jefferies Financial Group boosted their target price on Compass Therapeutics from $7.00 to $8.00 and gave the stock a “buy” rating in a report on Monday, February 10th. Guggenheim started coverage on Compass Therapeutics in a report on Monday, February 24th. They set a “buy” rating and a $12.00 price objective on the stock. HC Wainwright reaffirmed a “buy” rating and set a $10.00 price objective on shares of Compass Therapeutics in a report on Wednesday, January 8th. Piper Sandler started coverage on Compass Therapeutics in a report on Wednesday, February 19th. They set an “overweight” rating and a $12.00 price objective on the stock. Finally, D. Boral Capital reaffirmed a “buy” rating and set a $32.00 price objective on shares of Compass Therapeutics in a report on Tuesday, February 25th. Two investment analysts have rated the stock with a hold rating and seven have issued a buy rating to the stock. According to data from MarketBeat.com, the stock currently has a consensus rating of “Moderate Buy” and an average price target of $11.38.

Compass Therapeutics Company Profile

Compass Therapeutics, Inc, a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells.